Abbott Laboratories (ABT) Stock Research

Over a week ago

Abbott price target lowered by $10 at UBS, here's why

Jul 28, 8:11 AM

Freenome, Abbott announce FDA approval of SimpleScreen CRC

Jul 27, 8:10 AM

Abbott price target raised by $13 at BofA, here's why

Jul 17, 9:23 AM

Abbott price target raised by $10 at JPMorgan, here's why

Jul 17, 7:22 AM

Abbott price target raised by $3 at Piper Sandler, here's why

Jul 17, 7:06 AM

Abbott price target raised by $4 at Citi, here's why

Jul 17, 6:32 AM

What You Missed On Wall Street On Thursday

+25

Jul 16, 4:23 PM

Abbott's Q2 gives confidence in improving results, says William Blair

Jul 16, 3:33 PM

Midday Fly By: UnitedHealth, United Airlines, GE Aerospace report Q2 beats

+25

Jul 16, 12:08 PM

Abbott rises 10.7%

Jul 16, 12:00 PM

Abbott rises 12.5%

Jul 16, 10:01 AM

Abbott expects FX to have positive 1% impact on FY26 revenue

Jul 16, 9:57 AM

Early notable gainers among liquid option names on July 16th

Jul 16, 9:55 AM

Unusually active option classes on open July 16th

Jul 16, 9:40 AM

Abbott says on track for several critical trials in Q4

Jul 16, 9:13 AM

Morning Movers: UnitedHealth rises following second quarter beat

Jul 16, 8:54 AM

Abbott sees Q3 adjusted EPS $1.38-$1.46, consensus $1.42

Jul 16, 7:33 AM

Abbott raises FY26 adjusted EPS view to $5.45-$5.60 from $5.38-$5.58

Jul 16, 7:32 AM

Abbott reports Q2 adjusted EPS $1.31, consensus $1.28

Jul 16, 7:30 AM

Abbott price target lowered by $8 at Evercore ISI, here's why

Jul 6, 8:39 AM

Tandem Diabetes launches t:slim X2 compatibility with Abbott's FreeStyle

Jul 1, 8:35 AM

Abbott initiated with bullish view at Baird, here's why

Jul 1, 5:16 AM

Abbott initiated with bullish view at Baird

Jun 30, 4:18 PM

Trump Trade: Trump threatens tariffs on European countries over digital tax

Jun 29, 10:12 AM

Prosecutors prepped to charge Abbott, officials opted for settlement, WSJ says

Jun 29, 6:08 AM

Diversified Healthcare Portfolio: A broad product range spanning medical devices, diagnostics, nutrition, and established pharmaceuticals mitigates market risks and provides multiple avenues for growth.

Leading Innovation & R&D: Consistent, substantial investment in research and development drives the creation of novel, high-value products, such as the FreeStyle Libre system, ensuring a competitive technological edge.

Global Market Penetration: Extensive international presence, particularly in rapidly growing emerging markets, enables Abbott to reach a vast customer base and diversify its revenue streams geographically.

Regulatory Compliance Failures: Failure to adhere to complex and evolving global healthcare regulations can lead to product recalls, fines, market withdrawal, and reputational damage.

Product Liability and Quality Issues: Defects or perceived issues in medical devices, diagnostics, or nutritional products can result in patient harm, litigation, recalls, and loss of consumer trust.

Intense Market Competition: Abbott operates in highly competitive markets, facing pressure from rivals on pricing, innovation, and market share across its diverse product portfolio.

Charts